X4 Pharmaceuticals, IncXFOREarnings & Financial Report
X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.
XFOR Q1 FY2025 Key Financial Metrics
Revenue
$28.8M
Gross Profit
$24.1M
Operating Profit
$-9.4M
Net Profit
$282.0K
Gross Margin
83.6%
Operating Margin
-32.8%
Net Margin
1.0%
YoY Growth
N/A
EPS
$0.04
X4 Pharmaceuticals, Inc Q1 FY2025 Financial Summary
X4 Pharmaceuticals, Inc reported revenue of $28.8M for Q1 FY2025, with a net profit of $282.0K (up 100.5% YoY) (1.0% margin). Cost of goods sold was $4.7M, operating expenses totaled $33.5M.
Key Financial Metrics
| Total Revenue | $28.8M |
|---|---|
| Net Profit | $282.0K |
| Gross Margin | 83.6% |
| Operating Margin | -32.8% |
| Report Period | Q1 FY2025 |
X4 Pharmaceuticals, Inc Quarterly Revenue & Net Profit History
X4 Pharmaceuticals, Inc results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $28.8M | — | $282.0K | 1.0% |
| Q1 FY2024 | $0 | — | $-51.8M | N/A |
| Q3 FY2023 | $0 | — | $-2.3M | N/A |
| Q2 FY2023 | $0 | — | $-55.7M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $28.8M |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Assets | $173.4M | $173.3M | $112.2M | $130.0M |
| Liabilities | $105.9M | $105.7M | $111.1M | $107.1M |
| Equity | $67.5M | $67.6M | $1.0M | $22.9M |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Operating CF | $-47.9M | $-68.8M | $-33.6M | $-12.4M |